Dr. Liang Zicai is the founding Chairman and CEO of Suzhou Ribo Life Science Co. Ltd. Dr. Liang Zicai was the main founder of Ribo in 2007. He is responsible for formulating the strategy for development across the entire company, for the design and implementation of the R&D strategy for technological innovations in oligonucleotide therapeutics, and for overseeing the company's financial affairs. He is also in charge of the other responsibilities as delegated by Ribo and the board of directors.
Dr. Liang a major pioneer in the field of oligonucleotide technology and pharmaceuticals with more than 20 years' experience in research and development and has contributed to several national research programs. He previously served as a tenured professor, director of the office research and director of board of education in Peking University and the Deputy Chairman of the RNA Professional Committee of the Chinese Society of Biochemistry and Molecular Biology. He has held positions as both associate professor and research director at the Karolinska Institute in Sweden.
Dr. Liang Zicai obtained a Ph.D. from Uppsala University, Sweden, then completed postdoctoral research at Yale University in the United States.
Dr. Gan Liming is Co-CEO, and he serves as Ribo's Head of Global Product R&D and Chief Medical Officer (CMO), leading the formulation of global development strategy for innovative medicines, R&D operations, pipeline development and oversight of business development activities, and is responsible for the strategy formulation and operational management of the Rebel International R&D Center.
Dr. Gan previously worked for 20 years in R&D, operations, and management at the global pharmaceutical giant AstraZeneca. He possesses extensive strategic and practical experience which spans the entire lifecycle of R&D for innovative medicinal products and has led many joint projects in the field of nucleic acid drugs at AstraZeneca, participating in and overseeing the development of several non-small molecule drugs including peptides, antibodies, ASOs, cell therapy, and mRNA as the head and global vice president of clinical development for cardiovascular, renal, and metabolic diseases at AstraZeneca.
Dr. Gan holds a doctorate degree in medicine from the University of Gothenburg, Sweden, and obtained a Swedish medical practitioner's license.
Dr. Zhang Hongyan is one of Ribo's principal founders. Since 2007, she has served as president and is responsible for the management and operations of the entire organization.
Dr. Zhang has more than 20 years of experience in oligonucleotide technology and pharmaceuticals. Under her presidency, Ribo has established a professional and efficient R&D and industrialization organization, management and operation system from scratch, benchmarked against the innovation frontiers of global oligonucleotide technology, developed and established a oligonucleotide drug R&D platform covering the entire life cycle of oligonucleotide drugs from early stage of research and development to industrialization, and created a rich pipeline of oligonucleotide products covering a wide range of disease indications. Before joining Ribo, Dr. Zhang was a researcher at Sweden's Karolinska Institute and had founded two nucleic acid technology research and development companies in Sweden where she was responsible for the companies' operational management.
Dr. Zhang obtained a Ph.D. from Uppsala University, Sweden, then completed postdoctoral research at Yale University in the United States.
Mr. Zhang Su serves as the chief financial officer, secretary of the Board and joint company secretary. He is responsible for the overall financial management and Board affairs.
Mr. Zhang has over 20 years of experience in strategic and financial leadership in global investment banks, leading healthcare organizations and public pharmaceutical companies. Mr. Zhang's expertise spans equity research, corporate finance and capital markets operations, with a proven track record of driving value creation and investment decisions. Prior to joining Rebel, Mr. Zhang was the Chief Financial Officer of Wuhan Neurophth Biotechnology Limited Company and Ascentage Pharma Group International, where he was responsible for leading the company's strategic and financing initiatives. Earlier in his career, he also held senior positions at BNP Paribas and Standard Chartered Bank.
Mr. Zhang received a master’s degree in business administration from HEC School of Management and a master’s degree of science in accounting and finance from the London School of Economics and Political Science.
Dr. John Taylor serves as the Vice President and Global Head of Business Development, fully responsible for the global business development, promoting Ribo's oligonucleotide drug discovery and development technology platform and product pipeline for external cooperation.
Dr.Taylor has over 25 years of experience in the global biopharmaceutical industry and an academic background in DNA-protein recognition and biochemistry. Dr. Taylor worked in Business Development at AstraZeneca leading search and evaluation and executing transactions. He has also worked for Pfizer Global Research and Development conducting innovative R&D and leading projects. Dr. Taylor’s accomplished record in forging strategic partnerships and well-established connections across the pharmaceutical, biotechnology, and academic landscapes have been instrumental to our global collaboration initiatives.
Dr. Taylor obtained a Ph.D. from University of Bristol, British.
Dr.Tong Cheng serves as Executive Vice President of Ribo, leads the implementation of product development strategy, preclinical research, CMC development. Dr. Tong has been instrumental in establishing an efficient, integrated global R&D infrastructure and industry-leading CMC capabilities for oligonucleotide therapeutics.
Dr. Tong has more than 20 years of experience in drug discovery and development in international pharmaceutical companies and possesses complex technical management experience in the whole industry chain of R&D, registration and manufacturing in the field of innovative pharmaceuticals. Dr. Tong worked for Pfizer for many years, holding several senior scientific and leadership positions in the company's global R&D organization, including Senior Director of Pharmaceutical Sciences and General Manager of the Hisun-Pfizer Pharmaceuticals R&D Center.
Dr. Tong served as the chair and board member of the International Society for Pharmaceutical Engineering (ISPE) China and the chair of the APEC Asia-Pacific Council of the ISPE.
Dr. Tong received his Ph.D. in chemistry from Georgia Institute of Technology, USA.
Dr. Gao Shan serves as the senior vice president and Chief Scientific Officer of Ribo. He co-leads the development of breakthrough technologies, including RNA modification and delivery technology platforms. He is responsible for leading preclinical studies for a pipeline of drug candidates, including drug discovery and pharmacology studies in translational science.
Dr. Gao formerly worked as a senior researcher and associate professor at the Institute of Molecular Biology and Nano Research Center of Aarhus University in Denmark, engaged in nucleic acid technology and tumor research, and as an associate professor and deputy chief physician in the School and Hospital of Stomatology, Tianjin Medical University, engaged in clinical work and research.
He has also worked as an associate editor of Journal of Oral Pathology & Medicine and served as a visiting professor in Hebei Medical University.
Dr. Gao received his Ph.D. from the University of Copenhagen, Denmark.
Dr.Anders Gabrielsen serves as vice president and global head of clinical development, responsible for overseening the management of global clinical trail.
Dr. Gabrielsen is an experienced physician-scientist with over a decade of industry expertise in the cardiovascular, renal, and metabolism therapy area. Trained as a cardiologist and internist at the Karolinska Institutet and Karolinska University Hospital, Sweden, Dr. Gabrielsen specializes in heart failure and has played key roles in core clinical teams across all aspects of cardiology and internal medicine, with a focus on translational cardiovascular science. Dr. Gabrielsen’s work spans multiple mechanisms of action, indications, and product launches, with global industry experience from leading MNCs such as Bayer, Novartis, and AstraZeneca.
Dr. Gabrielsen received his Ph.D. from the University of Copenhagen, Denmank.
